No Data
Zhiguo Zheng Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) CEO Is the Most Bullish Insider, and Their Stock Value Gained 7.4%last Week
Zhejiang Ausun Pharmaceutical (603229.SH): The cooperative product Imatinib Mesylate Tablets has obtained overseas sales approval.
On December 20, Gelonghui reported that Zhejiang Ausun Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's wholly-owned subsidiary Eurogenerics has received marketing approval for Imatinib Mesylate Tablets from the Belgian Federal Agency for Medicines and Health Products. Imatinib Mesylate Tablets are the first Global targeted molecular therapy for oncology, used to treat patients in the chronic phase after acute phase, accelerated phase or failure of α-interferon therapy in chronic myeloid leukemia (CML), and those with malignant gastrointestinal tumors that cannot be surgically removed or have metastasized.
Ausun Pharma's Unit Gets Nod For Sitafloxacin Tablets' Registration
Zhejiang Ausun Pharmaceutical (603229.SH) subsidiary obtained a Pharmaceutical Registration Certificate for levofloxacin tablets.
Zhejiang Ausun Pharmaceutical (603229.SH) announced that recently, the company's wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd. [...]
gf sec: The upstream prices of penicillin and cephalosporins are fluctuating at a high level, while the active pharmaceutical ingredient is finding a bottom and stabilizing.
According to the data from the National Bureau of Statistics, in September 2024, the month-on-month PPI value of chemical drug active pharmaceutical ingredient manufacturing was 97.10, an increase of 2.0 compared to the previous month, and an increase of 1.63 from the average of 95.47 in the first half of 2024. Since the year 2023, when the month-on-month PPI of active pharmaceutical ingredient manufacturing fell below 100 for the whole year, the recent PPI value has been in an increasing state, indicating that the overall price of active pharmaceutical ingredients is in a phase of slight bottoming and recovery.
The Total Return for Zhejiang Ausun Pharmaceutical (SHSE:603229) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years
The Market Doesn't Like What It Sees From Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Earnings Yet As Shares Tumble 26%
No Data
